Usefulness of omalizumab in ten patients with severe occupational asthma.

Date publication

juin 2013

Journal

Allergy

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNIAUD Philippe

Tous les auteurs :
Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R, Mangiapan G, De Blay F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/23647648

Résumé

The management of severe occupational asthma (OA) remains problematic and new alternative treatments providing better disease control are required, ideally enabling affected individuals to remain in their job.

Mots clés

Adult, Anti-Asthmatic Agents, therapeutic use, Antibodies, Anti-Idiotypic, therapeutic use, Antibodies, Monoclonal, Humanized, therapeutic use, Asthma, Occupational, drug therapy, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Omalizumab, Severity of Illness Index, Treatment Outcome

Référence

Allergy. 2013 Jun;68(6):813-5